Literature DB >> 1604963

Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine treatment: case report.

R Capra1, N Marcianò, F Fieni, M Capucci, P Ferremi, A Orlandini.   

Abstract

We report the second case of thrombotic thrombocytopenic purpura occurring during ticlopidine therapy. A cerebral hemorrhage was the first sign of the thrombocytopenia. Even if thrombocytopenia is a rare occurrence with ticlopidine therapy, we stress that platelets must be repeatedly monitored.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1604963

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  5 in total

1.  Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.

Authors:  F L Paradiso-Hardy; C M Angelo; K L Lanctôt; E A Cohen
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

Review 2.  Platelet aggregation inhibitors in neurology.

Authors:  A Keyser
Journal:  Pharm World Sci       Date:  1993-12-17

3.  [Ticlopidine-associated thrombotic thrombocytopenic purpura (Morbus Moschcowitz)].

Authors:  J Carlsson; S Miketic; R Bätge; P Riedel; G Rahlf; U Tebbe
Journal:  Med Klin (Munich)       Date:  2000-01-15

Review 4.  Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.

Authors:  S Noble; K L Goa
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

Review 5.  Adverse haematological effects of ticlopidine. Prevention, recognition and management.

Authors:  B B Love; J Biller; M Gent
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.